FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 322:16-21 January 4, 1990 Number 1 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

Acute visceral leishmaniasis is associated with an antigen-specific immunosuppression of mononuclear cells as evidenced by defective in vitro production of interferon gamma. We evaluated treatment with recombinant human interferon gamma in combination with conventional pentavalent antimony therapy in patients with visceral leishmaniasis. Six of eight patients with visceral leishmaniasis (mean duration, 17 months) that had been unresponsive to multiple courses of pentavalent antimony responded to treatment with recombinant human interferon gamma (100 to 400 micrograms per square meter of body-surface area per day) in addition to pentavalent antimony (20 mg per kilogram of body weight per day) for 10 to 40 days. The other two patients improved initially but then relapsed and required treatment with amphotericin B. Eight of nine additional patients with previously untreated severe visceral leishmaniasis were also successfully treated with the combination of interferon gamma and pentavalent antimony. The 14 patients who responded to this regimen had marked improvement in symptoms and in measures of anemia and leukopenia, as well as weight gain, a decrease in spleen size, and an absence or reduction of leishmanias in splenic aspirates. These patients had no recurrence of illness after a mean (+/- SE) follow-up of 8 +/- 1 months. Fever was the only major side effect of interferon gamma. We conclude that the combination of interferon gamma and pentavalent antimony is effective in treating seriously ill patients with refractory or previously untreated visceral leishmaniasis.

Source Information

Universidade Federal da Bahia, Salvador, Brazil.

This article has been cited by other articles:

• Khouri, R., Bafica, A., Silva, M. d. P. P., Noronha, A., Kolb, J.-P., Wietzerbin, J., Barral, A., Barral-Netto, M., Van Weyenbergh, J. (2009). IFN-{beta} Impairs Superoxide-Dependent Parasite Killing in Human Macrophages: Evidence for a Deleterious Role of SOD1 in Cutaneous Leishmaniasis. J. Immunol. 182: 2525-2531 [Abstract] [Full Text]  
• Cordeiro-da-Silva, A., Borges, M. C., Guilvard, E., Ouaissi, A. (2001). Dual Role of the Leishmania major Ribosomal Protein S3a Homologue in Regulation of T- and B-Cell Activation. Infect. Immun. 69: 6588-6596 [Abstract] [Full Text]  
• Murray, H. W. (2001). Clinical and Experimental Advances in Treatment of Visceral Leishmaniasis. Antimicrob. Agents Chemother. 45: 2185-2197 [Full Text]  
• Steinmüller, C., Franke-Ullmann, G., Lohmann-Matthes, M.-L., Emmendörffer, A. (2000). Local Activation of Nonspecific Defense against a Respiratory Model Infection by Application of Interferon-gamma . Comparison between Rat Alveolar and Interstitial Lung Macrophages. Am. J. Respir. Cell Mol. Bio. 22: 481-490 [Abstract] [Full Text]  
• Ahuja, S. S., Mummidi, S., Malech, H. L., Ahuja, S. K. (1998). Human Dendritic Cell (DC)-Based Anti-Infective Therapy: Engineering DCs to Secrete Functional IFN-{gamma} and IL-12. J. Immunol. 161: 868-876 [Abstract] [Full Text]  
• Wandt, H., Frank, M., Ehninger, G., Schneider, C., Brack, N., Daoud, A., Fackler-Schwalbe, I., Fischer, J., Gackle, R., Geer, T., Harms, P., Loffler, B., Ohl, S., Otremba, B., Raab, M., Schonrock-Nabulsi, P., Strobel, G., Winter, R., Link, H. (1998). Safety and Cost Effectiveness of a 10 × 109/L Trigger for Prophylactic Platelet Transfusions Compared With the Traditional 20 × 109/L Trigger: A Prospective Comparative Trial in 105 Patients With Acute Myeloid Leukemia. Blood 91: 3601-3606 [Abstract] [Full Text]  
• Dries, D. J., Jurkovich, G. J., Maier, R. V., Clemmer, T. P., Struve, S. N., Weigelt, J. A., Stanford, G. G., Herr, D. L., Champion, H. R., Lewis, F. R., Hoyt, D., Hansbrough, J., Yellin, A. E., Berne, T. V., Trunkey, D. D., Jaffe, H. S., Munera, C., Fisher, P., Starko, K. M. (1994). Effect of Interferon Gamma on Infection-Related Death in Patients With Severe Injuries: A Randomized, Double-blind, Placebo-Controlled Trial. Arch Surg 129: 1031-1041 [Abstract]  
• Holland, S. M., Eisenstein, E. M., Kuhns, D. B., Turner, M. L., Fleisher, T. A., Strober, W., Gallin, J. I. (1994). Treatment of Refractory Disseminated Nontuberculous Mycobacterial Infection With Interferon Gamma: A Preliminary Report. NEJM 330: 1348-1355 [Abstract] [Full Text]  
• OZSOYLU, S. (1993). Treatment of Visceral Leishmaniasis With Meglumine and Allopurinol-Reply. Arch Pediatr Adolesc Med 147: 612-612 [Abstract]  
• OZSOYLU, S. (1992). Treatment of Visceral Leishmaniasis. Arch Pediatr Adolesc Med 146: 1021-1021 [Abstract]  
• Barral-Netto, M, Barral, A, Brownell, C., Skeiky, Y., Ellingsworth, L., Twardzik, D., Reed, S. (1992). Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257: 545-548 [Abstract]  
• Bottasso, O., Cabrini, J., Falcoff, R., Falcoff, E. (1992). Successful Treatment of an Antimony-Resistant American Mucocutaneous Leishmaniasis: A Case Report. Arch Dermatol 128: 996-997 [Abstract]  
• Baron, S., Tyring, S. K., Fleischmann, W. R. Jr, Coppenhaver, D. H., Niesel, D. W., Klimpel, G. R., Stanton, G. J., Hughes, T. K. (1991). The Interferons: Mechanisms of Action and Clinical Applications. JAMA 266: 1375-1383 [Abstract]